Promising combo for tough breast cancer hits early snag
NCT ID NCT04216472
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a combination of two drugs—nab-paclitaxel (a chemotherapy) and alpelisib (a targeted therapy)—in patients with triple-negative breast cancer that had specific genetic changes (PIK3CA or PTEN) and didn't respond to standard treatment. The goal was to shrink tumors before surgery. However, the study was stopped early after enrolling only 6 people, so we have very little data on how well it works or its side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nab-paclitaxel and alpelisib
What this could lead to
If successful, this combination could shrink tumors before surgery in patients with a hard-to-treat form of breast cancer that hasn't responded to standard chemotherapy.
What could go wrong
The trial was terminated early with only 6 participants, so results are very limited. It's unclear if the combination is safe or effective, and it only applies to patients with specific genetic mutations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States